(0.09%) 5 159.50 points
(0.10%) 38 872 points
(0.01%) 18 003 points
(0.65%) $78.62
(0.37%) $2.15
(0.60%) $2 322.50
(1.90%) $27.20
(0.10%) $966.25
(0.05%) $0.929
(-0.11%) $10.86
(-0.02%) $0.797
(0.41%) $91.83
2 days till quarter result
(bmo 2024-05-08)
Expected move: +/- 8.17%
3.37% $ 3.07
@ $4.90
Emitido: 14 feb 2024 @ 15:50
Retorno: -37.28%
Señal anterior: feb 14 - 13:56
Señal anterior:
Retorno: 2.30 %
Live Chart Being Loaded With Signals
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer...
Stats | |
---|---|
Volumen de hoy | 1.34M |
Volumen promedio | 2.26M |
Capitalización de mercado | 524.12M |
EPS | $0 ( 2024-05-01 ) |
Próxima fecha de ganancias | ( $-0.390 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.470 |
ATR14 | $0.00600 (0.20%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-22 | Moore Timothy L. | Sell | 17 360 | Common Stock |
2024-03-14 | Chang David D | Sell | 53 393 | Common Stock |
2024-01-30 | Parker Geoffrey M. | Buy | 190 | Common Stock |
2024-01-25 | Moore Timothy L. | Buy | 341 515 | Stock Option (Right to buy) |
2024-01-25 | Moore Timothy L. | Buy | 96 600 | Common Stock |
INSIDER POWER |
---|
93.40 |
Last 94 transactions |
Buy: 32 219 312 | Sell: 32 079 170 |
Volumen Correlación
Allogene Therapeutics Inc Correlación
10 Correlaciones Más Positivas | |
---|---|
HEPA | 0.96 |
ULCC | 0.955 |
JBLU | 0.953 |
RIDE | 0.953 |
NGM | 0.953 |
TCMD | 0.952 |
IMBI | 0.952 |
FNCH | 0.951 |
VCNX | 0.95 |
ALLR | 0.95 |
10 Correlaciones Más Negativas | |
---|---|
SKYA | -0.962 |
LEGA | -0.957 |
BRIV | -0.955 |
ADAL | -0.953 |
TBSAU | -0.951 |
TBSA | -0.95 |
CRZN | -0.949 |
LDHA | -0.949 |
FTPA | -0.949 |
AGGR | -0.949 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Allogene Therapeutics Inc Correlación - Moneda/Commodity
Allogene Therapeutics Inc Finanzas
Annual | 2023 |
Ingresos: | $95 000.00 |
Beneficio Bruto: | $-242.82M (-255 598.95 %) |
EPS: | $-2.09 |
FY | 2023 |
Ingresos: | $95 000.00 |
Beneficio Bruto: | $-242.82M (-255 598.95 %) |
EPS: | $-2.09 |
FY | 2022 |
Ingresos: | $243 000 |
Beneficio Bruto: | $-16.49M (-6 783.95 %) |
EPS: | $-2.30 |
FY | 2021 |
Ingresos: | $38.49M |
Beneficio Bruto: | $0.00 (0.00 %) |
EPS: | $-2.14 |
Financial Reports:
No articles found.
Allogene Therapeutics Inc
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico